If allowed to go into effect, argue Dean Rebouche and co-authors David S. Cohen and Greer Donley, a Fifth Circuit opinion rolling back FDA approval of mifepristone will serve only to harm patients.
Published on September 13, 2023
The 5th Circuit’s New Abortion Pill Ruling Targets Patients Directly
